136 related articles for article (PubMed ID: 31575355)
1. Impact of oral oncolytic initiation on medication adherence for pre-existing comorbid chronic conditions.
Dashputre AA; S Gatwood K; Schmidt J; Gatwood J
J Oncol Pharm Pract; 2020 Jun; 26(4):835-845. PubMed ID: 31575355
[TBL] [Abstract][Full Text] [Related]
2. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Dashputre AA; Gatwood KS; Gatwood J
J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
[TBL] [Abstract][Full Text] [Related]
3. Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions.
Gatwood J; Dashputre A; Rajpurohit A; Gatwood K; Mackler E; Wallace L; Farris K; Rizvi-Toner A; Farley J
J Oncol Pharm Pract; 2024 Mar; 30(2):342-353. PubMed ID: 37113049
[TBL] [Abstract][Full Text] [Related]
4. Medication Adherence Among Adults With Comorbid Chronic Conditions Initiating Oral Anticancer Agent Therapy for Multiple Myeloma.
Gatwood J; Dashputre A; Rajpurohit A; Gatwood K; Mackler E; Wallace L; Farris K; Rizvi-Toner A; Farley J
JCO Oncol Pract; 2022 Sep; 18(9):e1475-e1483. PubMed ID: 35700416
[TBL] [Abstract][Full Text] [Related]
5. Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies.
Academia EC; Mejías-De Jesús CM; Stevens JS; Jia LY; Yankama T; Patel C; Lee J
J Manag Care Spec Pharm; 2021 Oct; 27(10):1438-1446. PubMed ID: 34595953
[No Abstract] [Full Text] [Related]
6. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.
Mohammadi M; Cao Y; Glimelius I; Bottai M; Eloranta S; Smedby KE
BMC Cancer; 2015 Nov; 15():850. PubMed ID: 26537111
[TBL] [Abstract][Full Text] [Related]
7. Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Abuelgasim KA; Rehan H; Alsubaie M; Al Atwi N; Al Balwi M; Alshieban S; Almughairi A
J Med Case Rep; 2018 Mar; 12(1):64. PubMed ID: 29524963
[TBL] [Abstract][Full Text] [Related]
8. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Lam MS; Cheung N
J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
[TBL] [Abstract][Full Text] [Related]
9. Oral oncolytic treatment for chronic lymphocytic leukemia.
Harris V; Borlagdan J; Muluneh B
J Oncol Pharm Pract; 2022 Jun; 28(4):935-944. PubMed ID: 35084245
[TBL] [Abstract][Full Text] [Related]
10. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
Cole AL; Jazowski SA; Dusetzina SB
Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1529-1533. PubMed ID: 31507005
[TBL] [Abstract][Full Text] [Related]
11. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.
Gater A; Heron L; Abetz-Webb L; Coombs J; Simmons J; Guilhot F; Rea D
Leuk Res; 2012 Jul; 36(7):817-25. PubMed ID: 22364811
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma and chronic leukaemias in 2014: improved understanding of disease biology and treatment.
San-Miguel JF; Kantarjian HM
Nat Rev Clin Oncol; 2015 Feb; 12(2):71-2. PubMed ID: 25511190
[TBL] [Abstract][Full Text] [Related]
14. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients.
Laliberté F; Nelson WW; Lefebvre P; Schein JR; Rondeau-Leclaire J; Duh MS
Adv Ther; 2012 Aug; 29(8):675-90. PubMed ID: 22898791
[TBL] [Abstract][Full Text] [Related]
15. Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees.
Patel K; Sudhir VS; Kabadi S; Huang JC; Porwal S; Thakkar K; Pagel JM
J Oncol Pharm Pract; 2019 Dec; 25(8):1897-1906. PubMed ID: 30823852
[TBL] [Abstract][Full Text] [Related]
16. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension.
Piette JD; Heisler M; Ganoczy D; McCarthy JF; Valenstein M
Psychiatr Serv; 2007 Feb; 58(2):207-12. PubMed ID: 17287377
[TBL] [Abstract][Full Text] [Related]
17. Adherence trajectories in oral therapy for chronic myeloid leukemia: Overview of a research protocol.
Yeager KA; Waldrop-Valverde D; Paul S; Bruner DW; Klisovic R; Burns E; Mason TA; Patel N; Jennings BM
Res Nurs Health; 2020 Sep; 43(5):443-452. PubMed ID: 32866350
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Analysis of Red Bone Marrow Microenvironment Cells in Patients with Chronic Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphocytic Leukemia in the Dynamics of Chemotherapy.
Dolgikh TY; Kachesov IV; Tornuev VV; Vinogradova EV; Krinitsyna YM
Bull Exp Biol Med; 2018 Oct; 165(6):786-789. PubMed ID: 30353331
[TBL] [Abstract][Full Text] [Related]
19. Connection between Parameters of Erythron System and Myelofibrosis during Chronic Myeloleukemia, Multiply Mieloma, and Chronic Lymphatic Leukemia.
Dolgikh TY; Sholenberg EV; Kachesov IV; Senchukova SR
Bull Exp Biol Med; 2018 Jan; 164(3):382-385. PubMed ID: 29308562
[TBL] [Abstract][Full Text] [Related]
20. The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices.
Salgado TM; Mackler E; Severson JA; Lindsay J; Batra P; Petersen L; Farris KB
Support Care Cancer; 2017 Jun; 25(6):1797-1807. PubMed ID: 28108821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
